Clinical Trial Search

Primary: Change in Urinary Domain of the Expanded Prostate Cancer Index (EPIC) at Two Years — -4.12; -5.06 units on a scale — p=0.98

Primary: Use of Epidural Analgesia — 99; 103; 101 participants

Primary: Post-operative Pain Medication Requirements — 13.76; 17.32; 40.89; 46.63 MME — p=0.10

Primary: Percentage of Pairwise Comparisons With Wins of Clinical Benefit, a Composite of Death, Number of Heart Failure Events (HFEs), Time to the First HFE and ≥5-point…

Primary: Total Parenteral Opioid Use in IV Morphine Equivalents — 1.77; 1.95; 2.36 mg/Kg

Primary: Number of Participants With Composite Clinical Success (CCS) of Simplify Disc — 68; 132 Participants — p=<.001

Primary: Occurrence of Pain at Follow-up With Wide Opening, or Pain in the Temple, Jaw Joint or Jaw Muscles. — 26; 32; 54; 53 Participants

Primary: Composite of Mortality, Ongoing Need for Hospitalization, or Mechanical Ventilation at Day 15 — 9; 19 Participants — p=0.667

Primary: Time to First Event of Adjudicated Cardiovascular (CV) Death or Adjudicated Hospitalisation for Heart Failure (HHF) — 8.67; 6.86 Patients with event/100 pt-yrs at risk…

Primary: Time to Viral Relapse — NA; NA Months

Primary: Maximum Plasma Concentration (Cmax) Following Single Dose of Quizartinib With or Without Efavirenz — 130.0; 238.0; 11.0; 34.4 ng/mL

Primary: The Proportion of Subjects Achieving 2-point Reduction in the 5-point Investigator Global Assessment (IGA) for the Target Ulcer at Week 12 — 0 Participants — p=1

Primary: Efficacy of Assigned Intervention as Measured by Plasma Hemoglobin Value — 16.8; 17.3 g/dL — p=0.87

Primary: 30-Day Sustained Abstinence From Smoking — 69; 66; 10; 13 Participants

Primary: Time to Recovery — 3.4; 3.7; 3.9 Days